Association of mu-opioid receptor variants and response to citalopram treatment in major depressive disorder

American Journal of Psychiatry

Volumn 167, Issue 5, 2010, Pages 565-573

  Garriock, Holly A ^a   Tanowitz, Michael ^a   Kraft, Jeffrey B ^a   Dang, Vu C ^a   Peters, Eric J ^a   Jenkins, Greg D ^a   Reinalda, Megan S ^a   McGrath, Patrick J ^a   Von Zastrow, Mark ^a   Slager, Susan L ^a   Hamilton, Steven P ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; GLUTAMINE; HISTIDINE; MU OPIATE RECEPTOR;

AFRICAN AMERICAN; ARTICLE; CAUCASIAN; EXON; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HISPANIC; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MARKER GENE; PHENOTYPE; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; REMISSION; SINGLE NUCLEOTIDE POLYMORPHISM; STRATIFICATION; TREATMENT RESPONSE;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENETIC ASSOCIATION STUDIES; GENOTYPE; HAPLOTYPES; HISPANIC AMERICANS; HUMANS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; PSYCHIATRIC STATUS RATING SCALES; RECEPTORS, OPIOID, MU; TREATMENT OUTCOME;

EID: 77951778072     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2009.08081167     Document Type: Article

References (28)

1. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, Norquist G, Howland RH, Lebowitz B, McGrath PJ, Shores-Wilson K, Biggs MM, Balasubramani GK, Fava M; STAR*D Study Team: Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry 2006; 163:28-40
2. McMahon FJ, Buervenich S, Charney D, Lipsky R, Rush AJ, Wilson AF, Sorant AJ, Papanicolaou GJ, Laje G, Fava M, Trivedi MH, Wisniewski SR, Manji H: Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006; 78:804-814
3. Paddock S, Laje G, Charney D, Rush AJ, Wilson AF, Sorant AJM, Lipsky R, Wisniewski SR, Manji H, McMahon FJ: Association of GRIK4 with outcome of antidepressant treatment in the STAR*D cohort. Am J Psychiatry 2007; 164:1181-1188
4. Pan YX, Xu J, Mahurter L, Xu M, Gilbert AK, Pasternak GW: Identification and characterization of two new human mu opioid receptor splice variants, hMOR-1O and hMOR-1X. Biochem Biophys Res Commun 2003; 301:1057-1061
5. Pan YX, Xu J, Bolan E, Abbadie C, Chang A, Zuckerman A, Rossi G, Pasternak GW: Identification and characterization of three new alternatively spliced mu-opioid receptor isoforms. Mol Pharmacol 1999; 56:396-403
6. Pan YX: Diversity and complexity of the mu opioid receptor gene: alternative pre-mRNA splicing and promoters. DNA Cell Biol 2005; 24:736-750
7. Doyle GA, Sheng XR, Lin SS, Press DM, Grice DE, Buono RJ, Ferraro TN, Berrettini WH: Identification of three mouse mu-opioid receptor (MOR) gene (Oprm1) splice variants containing a newly identified alternatively spliced exon. Gene 2007; 388:135-147
8. Ide S, Han W, Kasai S, Hata H, Sora I, Ikeda K: Characterization of the 3′ untranslated region of the human mu-opioid receptor (MOR-1) mRNA. Gene 2005; 364:139-145
9. Pan L, Xu J, Yu R, Xu MM, Pan YX, Pasternak GW: Identification and characterization of six new alternatively spliced variants of the human mu opioid receptor gene, Oprm. Neuroscience 2005; 133:209-220
10. Hoehe MR, Kopke K, Wendel B, Rohde K, Flachmeier C, Kidd KK, Berrettini WH, Church GM: Sequence variability and candidate gene analysis in complex disease: association of mu opioid receptor gene variation with substance dependence. Hum Mol Genet 2000; 9:2895-2908
11. Bond C, LaForge KS, Tian M, Melia D, Zhang S, Borg L, Gong J, Schluger J, Strong JA, Leal SM, Tischfield JA, Kreek MJ, Yu L: Single-nucleotide polymorphism in the human mu opioid receptor gene alters beta-endorphin binding and activity: possible implications for opiate addiction. Proc Natl Acad Sci U S A 1998; 95:9608-9613
12. Zhang Y, Wang D, Johnson AD, Papp AC, Sadee W: Allelic expression imbalance of human mu opioid receptor (OPRM1) caused by variant A118G. J Biol Chem 2005; 280:32618-32624
13. Kennedy SE, Koeppe RA, Young EA, Zubieta JK: Dysregulation of endogenous opioid emotion regulation circuitry in major depression in women. Arch Gen Psychiatry 2006; 63:1199-1208
14. 2-adrenoceptors and mu-opioid receptors in the guinea pig cortex and hippocampus. Eur J Pharmacol 2008; 579:116-125
15. Chen F, Lawrence AJ: Chronic antidepressant treatment causes a selective reduction of mu-opioid receptor binding and functional coupling to G proteins in the amygdala of fawn-hooded rats. J Pharmacol Exp Ther 2004; 310:1020-1026
16. Lekman M, Paddock S, McMahon FJ: Pharmacogenetics of major depression: insights from level 1 of the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial. Mol Diagn Ther 2008; 12:321-330
17. Lin E, Chen PS: Pharmacogenomics with antidepressants in the STAR*D study. Pharmacogenomics 2008; 9:935-946
18. Kraft JB, Peters EJ, Slager SL, Jenkins GD, Reinalda MS, McGrath PJ, Hamilton SP: Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol Psychiatry 2007; 61:734-742
19. Rush AJ, Bernstein IH, Trivedi MH, Carmody TJ, Wisniewski S, Mundt JC, Shores-Wilson K, Biggs MM, Woo A, Nierenberg AA, Fava M: An evaluation of the Quick Inventory of Depressive Symptomatology and the Hamilton Rating Scale for Depression: a Sequenced Treatment Alternatives to Relieve Depression trial report. Biol Psychiatry 2006; 59:493-501
20. Peters EJ, Slager SL, Kraft JB, Jenkins GD, Reinalda MS, McGrath PJ, Hamilton SP: Pharmacokinetic genes do not influence response or tolerance to citalopram in the STAR*D sample. PLoS One 2008; 3:e1872
21. Freidlin B, Zheng G, Li Z, Gastwirth JL: Trend tests for case-control studies of genetic markers: power, sample size and robustness. Hum Hered 2002; 53:146-152
22. Price AL, Patterson NJ, Plenge RM, Weinblatt ME, Shadick NA, Reich D: Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006; 38:904-909
23. Nyholt DR: A simple correction for multiple testing for single-nucleotide polymorphisms in linkage disequilibrium with each other. Am J Hum Genet 2004; 74:765-769
24. Walwyn WM, Keith DE Jr, Wei W, Tan AM, Xie CW, Evans CJ, Kieffer BL, Maidment NT: Functional coupling, desensitization and internalization of virally expressed mu opioid receptors in cultured dorsal root ganglion neurons from mu opioid receptor knockout mice. Neuroscience 2004; 123:111-121
25. Keith DE, Murray SR, Zaki PA, Chu PC, Lissin DV, Kang L, Evans CJ, von Zastrow M: Morphine activates opioid receptors without causing their rapid internalization. J Biol Chem 1996; 271:19021-19024
26. Garriock HA, Kraft JB, Shyn SI, Peters EJ, Yokoyama JS, Jenkins GD, Reinalda MS, Slager SL, McGrath PJ, Hamilton SP: A genomewide association study of citalopram response in major depressive disorder. Biol Psychiatry 2010; 67:133-138
27. Peters EJ, Slager SL, Jenkins GD, Reinalda MS, Garriock HA, Shyn SI, Kraft JB, McGrath PJ, Hamilton SP: Resequencing of serotonin-related genes and association of tagging SNPs to citalopram response. Pharmacogenet Genomics 2009; 19:1-10
28. Zubieta JK, Bueller JA, Jackson LR, Scott DJ, Xu Y, Koeppe RA, Nichols TE, Stohler CS: Placebo effects mediated by endogenous opioid activity on mu-opioid receptors. J Neurosci 2005; 25:7754-7762